{
    "nctId": "NCT01390818",
    "briefTitle": "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors",
    "officialTitle": "An Open-Label, Phase Ib Dose Escalation Trial of Oral Combination Therapy With MSC1936369B and SAR245409 in Subjects With Locally Advanced or Metastatic Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Melanoma, Colorectal Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 146,
    "primaryOutcomeMeasure": "Number of Subjects With Dose Limiting Toxicities (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject with advanced solid tumors for which there is no approved therapy:\n\n  * Advanced solid tumor with diagnosed alteration in one or more of the following genes (PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 and/or\n  * A histologically or cytologically confirmed diagnosis of one of the following solid tumors: pancreatic, thyroid, colorectal, non-small cell lung, endometrial, renal, breast, ovarian carcinoma and melanoma\n* Subject with archived tumor tissue available for transfer to the Sponsor\n* Subject enrolled at lower dose level cohorts and MTD expansion cohorts must have tumor available for biopsy and agree to pre-treatment and on-treatment tumor biopsies\n* Subject has measurable or evaluable disease by response evaluation criteria in solid tumors (RECIST) v1.1\n* Subject is aged greater than or equal to (\\>=) 18 years\n* Subjects enrolled in disease specific expansion cohorts must fulfill all the inclusion/exclusion criteria listed above with the following restriction to the Inclusion Criterion number 1:\n\n  * Relapsed or refractory Kirsten rat sarcoma viral oncogene homolog (KRAS) or neuroblastoma RAS viral oncogene homolog (NRAS) mutated metastatic non-small cell lung cancer (NSCLC) with no approved therapies, or\n  * Relapsed or refractory metastatic triple negative breast cancer defined as estrogen, progesterone and HER2 negative carcinoma of the breast with no approved therapies, or\n  * Relapsed or refractory metastatic colorectal cancer (CRC) with dual KRAS and PIK3CA mutation with no approved therapies, or\n  * BRAF V600E/K mutated unresectable or metastatic melanoma after progression on B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors\n* Other protocol-defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Subject has been previously treated with a PI3K inhibitor or a MEK inhibitor and taken off treatment due to treatment related adverse events\n* Subject has received:\n* Chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anti-cancer therapy within 28 days of trial drug treatment\n* Any investigational agent within 28 days of trial drug treatment\n* Extensive prior radiotherapy on more than 30% bone marrow reserves, or prior bone marrow/stem cell transplantation\n* Subject has not recovered from toxicity due to prior therapy\n* Subject has poor organ and marrow function as defined in the protocol\n* Subject has a history of central nervous system metastases, unless subject has been previously treated for CNS metastases\n* Subject has a history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease\n* Subject has a history of recent major surgery or trauma within the last 28 days.\n* Subject has participated in another clinical trial within the past 30 days\n* Other protocol-defined exclusion criteria could apply",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}